…
Monash IVF Group Limited engages in the provision of assisted reproductive genetic and specialist women imaging services in Australia and Southeast Asia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. The company also provides tertiary level prenatal diagnostic, ultrasound, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Cremorne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Monash IVF Group is an Australian provider of assisted reproductive services operating a network of fertility clinics, diagnostic and laboratory services primarily in Australia and New Zealand. Long-term growth may be supported by later childbearing, greater use of assisted reproductive technologies and expansion of diagnostics, and investors may find the company attractive for exposure to recurring healthcare services.
Key risks include changes to government funding and regulation of fertility services, competition and pricing pressure, and operational dependence on clinical outcomes and specialist staff that could affect demand and reputation.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 11.38M | 36.12M | -10.66M | 29.84M | 26.22M |
| Minority interest | - | - | -0.58M | -0.13M | -0.10M |
| Net income | 7.42M | 25.01M | -6.53M | 21.84M | 18.41M |
| Selling general administrative | - | 15.76M | 88.82M | 74.13M | 66.88M |
| Selling and marketing expenses | - | 8.06M | 7.72M | 6.92M | 6.43M |
| Gross profit | 61.93M | 90.31M | 85.50M | 191.19M | 172.51M |
| Reconciled depreciation | - | - | 18.58M | 15.34M | 14.79M |
| Ebit | 20.68M | 44.17M | -7.80M | 31.07M | 26.65M |
| Ebitda | 44.03M | 53.01M | 10.78M | 46.41M | 41.44M |
| Depreciation and amortization | 23.35M | 8.84M | 18.58M | 15.34M | 14.79M |
| Operating income | 20.68M | 43.41M | -5.61M | 35.00M | 28.37M |
| Other operating expenses | 248.78M | 228.50M | 260.57M | 101.04M | 87.70M |
| Interest expense | 9.20M | 7.39M | 5.37M | 1.23M | 0.43M |
| Tax provision | - | 10.45M | -4.71M | 7.87M | 7.72M |
| Interest income | - | 7.29M | 0.06M | 0.03M | 0.00M |
| Net interest income | - | - | -5.31M | -3.28M | -2.15M |
| Income tax expense | 3.06M | 10.45M | -4.71M | 7.87M | 7.72M |
| Total revenue | 269.46M | 271.92M | 254.96M | 213.59M | 192.29M |
| Total operating expenses | 41.26M | 46.90M | 91.11M | 158.07M | 144.14M |
| Cost of revenue | 207.53M | 181.60M | 169.46M | 22.40M | 19.79M |
| Total other income expense net | -9.29M | -7.29M | -5.05M | -5.16M | -2.15M |
| Net income from continuing ops | - | - | -5.95M | 21.97M | 18.50M |
| Net income applicable to common shares | - | 25.01M | -6.53M | 21.84M | 18.41M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 512.35M | 492.61M | 508.47M | 421.89M | 380.82M |
| Intangible assets | 22.20M | 23.88M | - | 25.32M | 25.72M |
| Other current assets | 7.29M | 15.34M | 5.68M | 4.98M | 4.06M |
| Total liab | 258.88M | 242.19M | 261.81M | 146.82M | 110.92M |
| Total stockholder equity | 249.16M | 246.28M | 241.91M | 273.20M | 267.92M |
| Other current liab | 37.67M | 45.89M | 30.44M | 5.71M | 0.48M |
| Common stock | 506.79M | 506.79M | 506.79M | 506.79M | 506.79M |
| Capital stock | - | - | - | 506.79M | 506.79M |
| Retained earnings | -162.74M | -117.14M | -162.74M | -162.74M | -162.74M |
| Other liab | - | - | - | 6.61M | 2.65M |
| Good will | 273.35M | 273.35M | 273.35M | 255.13M | 233.17M |
| Other assets | - | - | - | 0.68M | 0.17M |
| Cash | 8.84M | 9.43M | 11.33M | 8.01M | 7.87M |
| Cash and equivalents | - | - | - | 1.44M | 0.97M |
| Total current liabilities | 65.74M | 61.41M | 118.82M | 46.50M | 38.17M |
| Current deferred revenue | 11.86M | - | 77.32M | 32.61M | 27.22M |
| Net debt | 190.78M | 170.88M | 124.04M | 92.03M | 69.36M |
| Short term debt | 11.17M | 9.75M | 7.99M | 6.33M | 7.13M |
| Short long term debt total | 199.62M | 180.31M | 135.37M | 100.04M | 77.23M |
| Other stockholder equity | - | - | -0.00M | -409.41M | -404.71M |
| Property plant equipment | - | - | - | 109.39M | 95.06M |
| Total current assets | 44.12M | 41.68M | 55.78M | 29.94M | 25.64M |
| Long term investments | - | - | - | 1.28M | 1.05M |
| Net tangible assets | - | - | - | -7.25M | 9.02M |
| Short term investments | - | - | - | 0.30M | - |
| Net receivables | 17.62M | 7.91M | 30.59M | 10.53M | 8.45M |
| Long term debt | - | - | - | 38.87M | 9.76M |
| Inventory | 10.37M | 9.00M | 8.18M | 6.43M | 5.25M |
| Accounts payable | 5.05M | 5.78M | 3.08M | 1.85M | 3.34M |
| Accumulated other comprehensive income | -94.89M | -143.37M | -102.15M | -70.85M | -76.13M |
| Non currrent assets other | - | 6.32M | 23.97M | 0.47M | -355.00M |
| Non current assets total | 468.23M | 450.92M | 452.69M | 391.96M | 355.17M |
| Capital lease obligations | - | - | - | 61.17M | 67.47M |
| Long term debt total | - | - | - | 93.71M | 70.10M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | -38.80M | -40.51M | -15.16M |
| Change to liabilities | - | - | - | 1.96M | 0.68M |
| Total cashflows from investing activities | -23.77M | -17.43M | -38.80M | -40.51M | -15.16M |
| Net borrowings | - | - | 21.00M | 19.82M | -0.26M |
| Total cash from financing activities | -6.85M | 2.67M | -10.39M | 1.51M | -17.63M |
| Change to operating activities | - | - | - | 1.15M | 0.35M |
| Net income | 7.42M | 25.01M | -6.53M | 21.84M | 18.41M |
| Change in cash | -0.58M | -1.91M | 3.33M | 0.13M | -0.89M |
| Begin period cash flow | 9.43M | 11.33M | 8.01M | 7.87M | 8.76M |
| End period cash flow | 8.84M | 9.43M | 11.33M | 8.01M | 7.87M |
| Total cash from operating activities | 30.20M | 12.90M | 52.52M | 39.12M | 31.89M |
| Depreciation | 23.35M | 22.34M | 18.58M | 12.88M | 12.35M |
| Other cashflows from investing activities | - | -1.96M | -0.85M | -12.72M | -3.40M |
| Dividends paid | 4.68M | -19.87M | -18.32M | 17.14M | 16.75M |
| Change to inventory | -1.37M | -0.82M | -1.75M | -1.18M | -1.04M |
| Change to account receivables | -0.58M | 15.44M | -20.57M | -2.98M | -2.70M |
| Other cashflows from financing activities | -13.18M | -4.02M | -13.07M | 31.65M | 17.25M |
| Change to netincome | - | - | - | 3.13M | 4.07M |
| Capital expenditures | 22.93M | 12.43M | 20.82M | 27.79M | 11.76M |
| Change in working capital | -1.47M | 15.60M | -21.00M | -4.16M | -3.74M |
| Stock based compensation | - | 0.77M | 0.32M | 0.32M | 0.25M |
| Other non cash items | 0.90M | -50.82M | 61.46M | 4.40M | 1.13M |
| Free cash flow | 7.27M | 0.47M | 31.70M | 11.33M | 20.13M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MVF Monash Ivf Group Ltd |
- -% |
0.74 | 37.00 | 16.21 | 1.07 | 1.17 | 1.79 | 11.73 |
| SHL Sonic Healthcare Ltd |
0.18 0.91% |
20.06 | 16.16 | 17.21 | 0.90 | 1.15 | 1.36 | 8.10 |
| IDX Integral Diagnostics Ltd |
0.01 0.58% |
1.74 | 28.83 | 15.24 | 0.82 | 0.97 | 1.52 | 9.49 |
| ACL Australian Clinical Labs Ltd |
0.04 1.25% |
3.24 | 26.67 | 16.84 | 0.81 | 3.95 | 1.24 | 5.12 |
| HLS Healius Ltd |
0.01 1.01% |
0.50 | - | 29.24 | 0.26 | 2.08 | 0.94 | 10.14 |
Monash IVF Group Limited engages in the provision of assisted reproductive genetic and specialist women imaging services in Australia and Southeast Asia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. The company also provides tertiary level prenatal diagnostic, ultrasound, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Cremorne, Australia.
510 Church Street, Cremorne, VIC, Australia, 3121
61 3 9420 8235
892
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael D. Knaap | CEO, MD & Exec. Director | NA |
| Mr. Malik Jainudeen | Group CFO & Company Sec. | NA |
| Dr. Hamish Hamilton | Chief Operating Officer | NA |
| Dr. Richard Charles Henshaw M.D. | Exec. Director | NA |
| Dr. Deirdre Zander-Fox BSc. (Hons.), Dip. of Mgt, Ph.D. | Chief Scientific Officer | NA |
| Mr. Thierry Panthier | Chief Information Officer | NA |
| Ms. Fiona Allen | Chief Marketing Officer | NA |
| Ms. Peggy North | Chief People & Culture Officer | NA |
| Ms. Tedd Fuell | Chief Governance & Risk Officer | NA |
| Ms. Clementina Singh | Gen. Mang. of New South Wales | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.